Granite Point Capital Management, L.P. Taysha Gene Therapies, Inc. Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$11.43 - $19.2 $457,200 - $768,000	-40,000 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$15.82 - $21.57 $158,200 - $215,700	-10,000 Reduced 20.0%	40,000 $745,000
Q2 2021 Aug 16, 2021	BUY	$19.29 - $26.38 $964,500 - $1.32 Million	50,000 New	50,000 $1.06 Million

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $82.2M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.